Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease - Top-Institutions - MDSpire

Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease

  • By

  • Qiumei Zhu

  • Shitao Feng

  • Zhende Yan

  • Zijian Wang

  • Xinran Huang

  • Changning Sun

  • Bingqiang Zhang

  • Xinrui Li

  • Yuchao Gu

  • July 2, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Institute of Microbiology, Chinese Academy of Sciences
    Institute of Microbiology, Chinese Academy of Sciences

    Beijing, Beijing

    Key Differentiators

    • Microbiology

  • #2

    Stem Cell Bank, Chinese Academy of Sciences
    Stem Cell Bank, Chinese Academy of Sciences

    Beijing, Beijing

    Key Differentiators

    • Stem Cell Research

  • #3

    NYU Langone Health
    NYU Langone Health

    New York, New York

    Key Differentiators

    • Gastroenterology

  • #4

    University Hospital of the Princess
    University Hospital of the Princess

    Madrid, Madrid

    Key Differentiators

    • Gastroenterology

  • #5

    Guy’s and St Thomas’ NHS Foundation Trust
    Guy’s and St Thomas’ NHS Foundation Trust

    London, England

    Key Differentiators

    • Gastroenterology

Original Source(s)

Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease

  • by Qiumei Zhu, Shitao Feng, Zhende Yan, Zijian Wang, Xinran Huang, Changning Sun, Bingqiang Zhang, Xinrui Li, Yuchao Gu

  • July 2, 2026

Related Content

Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis

Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue

Deep learning-based quantitative histopathology of endoscopic biopsies in Crohn’s disease: a retrospective cross-sectional validation study